New! Sign up for our free email newsletter.
Science News
from research organizations

Potential new treatment for multiple sclerosis

Date:
April 27, 2015
Source:
Gladstone Institutes
Summary:
Scientists have discovered a way to prevent the development of multiple sclerosis in mice. Using a drug that blocks the production of a certain type of immune cell linked to inflammation and autoimmunity, the researchers successfully protected against the onset of MS in an animal model of the disease. The scientists say the next step is to test this strategy using other autoimmune disorders.
Share:
FULL STORY

Scientists from the Gladstone Institutes have discovered a way to prevent the development of multiple sclerosis (MS) in mice. Using a drug that blocks the production of a certain type of immune cell linked to inflammation and autoimmunity, the researchers successfully protected against the onset of MS in an animal model of the disease. The scientists say the next step is to test this strategy using other autoimmune disorders.

"We are very excited about these findings," says Eric Verdin, MD, a senior investigator at Gladstone and co-senior author on the study. "In light of the significant effect the treatment had on inflammation, the implications of these results will likely extend beyond multiple sclerosis to other types of autoimmune disorders. We are particularly interested in testing this in type I diabetes given the similar pathways involved, and we are already seeing very promising results in preliminary experiments."

In the immune system, two kinds of T cells strike a delicate balance--T helper cells (Th17) activate the immune system, protecting against infections and cancers, while regulatory T cells (Tregs) suppress the system, keeping it in check. A disparity between these cell types, where there are too many Th17 and not enough Tregs, can lead to a hyperactive immune system, resulting in inflammation, tissue damage, and autoimmune disease.

In the current study, published in the Journal of Experimental Medicine, the researchers discovered that an important regulatory protein, sirtuin 1 (SIRT1), is involved in the production of Th17 cells. By blocking this protein, the scientists can protect against the onset of autoimmunity. SIRT1 also has a negative impact on Treg maturation and maintenance, so inhibiting its expression simultaneously enhances the production of Tregs and suppresses the creation of Th17.

To test this effect on disease, the researchers used a mouse model of MS and treated the animals with a drug that inhibits SIRT1. Typically, MS-model mice experience severe motor problems, eventually leading to paralysis, but when they were given the drug the mice behaved perfectly normally. Moreover, the treated animals showed no signs of inflammation or cell damage in their spines, classic markers for MS.

In contrast with the current research, SIRT1 is typically thought of as having anti-inflammatory properties, and compounds that increase SIRT1--like resveratrol--have been proposed as a way to delay aging. However, first author Hyungwook Lim, PhD, a postdoctoral fellow at Gladstone, says the new research suggests that the protein's effects are more complicated.

"The conventional theory has been that you should activate SIRT1 to improve health and longevity, but we show that this can have negative consequences," says Dr. Lim. "Instead, we think the role of SIRT1 very much depends on the type of tissue being targeted. For instance, in immune cells, instead of being anti-inflammatory SIRT1 appears to have a pro-inflammatory role, which makes it a prime target to treat autoimmune disorders."


Story Source:

Materials provided by Gladstone Institutes. Note: Content may be edited for style and length.


Journal Reference:

  1. Hyung W. Lim, Seung Goo Kang, Jae Kyu Ryu, Birgit Schilling, Mingjian Fei, Intelly S. Lee, Amanuel Kehasse, Kotaro Shirakawa, Masaru Yokoyama, Martina Schnölzer, Herbert G. Kasler, Hye-Sook Kwon, Bradford W. Gibson, Hironori Sato, Katerina Akassoglou, Changchun Xiao, Dan R. Littman, Melanie Ott, and Eric Verdin. SIRT1 deacetylates RORγt and enhances Th17 cell generation. Journal of Experimental Medicine, 2015 DOI: 10.1084/jem.20132378

Cite This Page:

Gladstone Institutes. "Potential new treatment for multiple sclerosis." ScienceDaily. ScienceDaily, 27 April 2015. <www.sciencedaily.com/releases/2015/04/150427101622.htm>.
Gladstone Institutes. (2015, April 27). Potential new treatment for multiple sclerosis. ScienceDaily. Retrieved March 28, 2024 from www.sciencedaily.com/releases/2015/04/150427101622.htm
Gladstone Institutes. "Potential new treatment for multiple sclerosis." ScienceDaily. www.sciencedaily.com/releases/2015/04/150427101622.htm (accessed March 28, 2024).

Explore More

from ScienceDaily

RELATED STORIES